JPMorgan Chase & Co. Has $1.52 Million Position in AnaptysBio, Inc. (NASDAQ:ANAB)

JPMorgan Chase & Co. grew its position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 240.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 114,939 shares of the biotechnology company's stock after buying an additional 81,195 shares during the period. JPMorgan Chase & Co. owned 0.38% of AnaptysBio worth $1,522,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its stake in AnaptysBio by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock worth $24,411,000 after acquiring an additional 143,584 shares during the last quarter. Victory Capital Management Inc. boosted its position in shares of AnaptysBio by 41.0% during the fourth quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company's stock worth $4,428,000 after purchasing an additional 97,200 shares in the last quarter. Barclays PLC grew its holdings in shares of AnaptysBio by 117.4% in the 3rd quarter. Barclays PLC now owns 44,300 shares of the biotechnology company's stock valued at $1,486,000 after buying an additional 23,926 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in AnaptysBio during the 4th quarter worth $311,000. Finally, Geode Capital Management LLC grew its stake in AnaptysBio by 3.0% in the third quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company's stock valued at $15,594,000 after acquiring an additional 13,336 shares during the period.

AnaptysBio Stock Performance

Shares of ANAB stock traded down $0.51 during midday trading on Thursday, hitting $21.71. 71,686 shares of the company were exchanged, compared to its average volume of 590,881. AnaptysBio, Inc. has a 52 week low of $12.21 and a 52 week high of $41.31. The firm has a market capitalization of $665.78 million, a P/E ratio of -3.57 and a beta of -0.09. The firm's 50 day moving average price is $18.07 and its two-hundred day moving average price is $19.40.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.61) by $0.89. The company had revenue of $43.11 million during the quarter, compared to analysts' expectations of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. Analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio declared that its Board of Directors has approved a stock buyback plan on Monday, March 24th that authorizes the company to repurchase $75.00 million in shares. This repurchase authorization authorizes the biotechnology company to buy up to 13.1% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

ANAB has been the topic of several recent research reports. Guggenheim reissued a "buy" rating on shares of AnaptysBio in a research note on Monday, March 3rd. Wolfe Research initiated coverage on AnaptysBio in a research report on Tuesday, February 4th. They set an "outperform" rating and a $25.00 price target for the company. HC Wainwright reissued a "neutral" rating and issued a $22.00 price objective on shares of AnaptysBio in a research report on Tuesday, March 4th. JPMorgan Chase & Co. raised their target price on shares of AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Finally, Wells Fargo & Company raised their price objective on AnaptysBio from $40.00 to $51.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, AnaptysBio has an average rating of "Moderate Buy" and an average target price of $33.63.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.